A Phase 4 Study of Venetoclax in Combination With Azacitidine in Newly Diagnosed Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy in China
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors AbbVie
- 27 Jun 2023 Planned End Date changed from 26 Jul 2024 to 28 Jul 2024.
- 27 Jun 2023 Planned primary completion date changed from 26 Jul 2024 to 28 Jul 2024.
- 26 Oct 2022 Status changed from recruiting to active, no longer recruiting.